

The Cholesterol Dilemma – A Possible Family Affair

Reactor

Sioksoan Chan Cua, MD, MSc, FPPS, FPSPME

Pediatric Endocrinologist
Consultant, Philippine General Hospital

Outline

- Clinical burden of dyslipidemia
 - Dyslipidemia in children
- Clinical Features of FH
 - Homozygous and heterozygous FH
 - Screening and diagnosis
- Early identification of FH and reduction of the burden of disease

Clinical burden of dyslipidemia – Dr. JDA Magno

- Dyslipidemia in children
 - Childhood obesity
 - Familial hypercholesterolemia (FH) - Undiagnosed/ underdiagnosed
 - Elevated LDL cholesterol at birth → adolescent → young adult
- FH
 - A tale of 2 sisters: sister A 16 y of age (adolescent)
 - Strong family history of heart attacks and strokes (mostly <55 years)
- CV Impact of dyslipidemia: increased risks of CV death
 - Early recognition and treatment: primary and secondary prevention
 - ↓ complications of **ASCVD** (Atherosclerotic Cardiovascular Disease)

Clinical Features of FH and Cascade Screening

- Dr. R Sy

In children with

- homozygous FH
 - Cutaneous xanthoma: elbows, hands, knees, feet, buttocks
 - no medical consultation
 - undiagnosed, misdiagnosed
 - no referrals and no tests
- heterozygous FH
 - Often asymptomatic
 - family history of cardiometabolic diseases and premature death



PPS: Familial hypercholesterolemia

- Familial hypercholesterolemia (ICD-10): E 78.
- PPS in-patient registry (January 2006 to April 2022)
 - Too few; undiagnosed; under-reporting

9 out of 4,933,550 cases

ICD	Diagnosis	Cases
E78	Disorders of lipoprotein metabolism and other lipidaemias	9

- Heterozygous FH: ~ 1 in 200 to 300 individuals (1:250)
- Homozygous FH: ~ 1:300,000 to 1:400,000.

FM

- Diagnostic tests
 - Lipid panels: Cholesterol, LDL
 - Genetic analysis: mutations in LDLR, PCSK9 and APOB genes
- Screening
 - Universal: at age 10 y (9-11 y and 17-21 y)
 - Selective: at risk - there is a (+) family history of premature CVD or death
 - Screening at 5-10 years, college applicants (~18 years)
- Cascade screening - cost effective
 - ↓ the 10 y incidence of coronary heart disease (CHD) from 50% to 25%
 - An overall gain of ~25 life-years and 29 quality-adjusted life years

Cholesterol Metabolism – Dr. LE Santos

- Characteristics of homozygous and heterozygous FH

Characteristics of Homozygous and Heterozygous FH		
	HeFH	HoFH
Genetic mutation ¹	One mutated allele	Two mutated alleles
Prevalence ¹⁻⁴	More prevalent	Less prevalent
Total cholesterol ^{1,5}	310–580 mg/dL	460–1160 mg/dL
LDL-C levels ¹⁻⁴	≥ 190 mg/dL	> 500 mg/dL
Physical presentation ^{1-3,6}	Xanthomas ^a or corneal arcus	Xanthomas ^a or corneal arcus <u>in childhood</u>
Acute Myocardial Infarction ^{2,6,7}	Usually > 30 years old	Early <u>childhood/adolescence^b</u>
CHD development ^{1-3,5}	< 55–60 years	<u>Childhood/adolescence^c</u>

Underdiagnosed, undiagnosed

Rarer Symptomatic

Cholesterol Dilemma

1. NCEP. *Circulation*. 2002;106:3143-3421. 2. Raal FJ, et al. *Atherosclerosis*. 2012;223:262-268. 3. Reiner Z. *Nat Rev Cardiol*. 2015;12:565-575. 4. Robinson JG. *J Manag Care Pharm*. 2013;19:139-149. 5. Nordestgaard BG, et al. *Eur Heart J*. 2013;34:3478-3490a. 6. Cuchel M, et al. *Eur Heart J*. 2014;35:2146-2157. 7. Goldstein JL, et al. *Arterioscler Thromb Vasc Biol*. 2009;29:431-438. 8. Soutar AK and Naoumova RP. *Nat Clin Pract Cardiovasc Med*. 2007;4(4):214-225.

Cases of FH, homozygous (seen in ped endo clinics)

18 y, F

- Strong family hx of premature CVD



- Tendon xanthomas
- Atherosclerotic retinopathy
- LDL Cholesterol > 2000 mg/dL
- Treatment: statin (Simvastatin)

Data of K Albano. PGH

6y, F


- Maternal grandmother died at ~ 46y



- Tendon xanthoma
- LDL Cholesterol > 500-600 mg/dL
- Treatment: statin (atorvastatin)

Data of S Cua. MDH

FH in children – The LANCET Child & Adolescent Health. 2021



THE LANCET
Child & Adolescent Health

REVIEW | VOLUME 5, ISSUE 9, P652-661, SEPTEMBER 01, 2021

Advances in familial hypercholesterolaemia in children

M Doortje Reijman, MD • D Meeike Kusters, MD •

Albert Wiegman, MD  

Published: June 10, 2021 •

DOI: [https://doi.org/10.1016/S2352-4642\(21\)00095-X](https://doi.org/10.1016/S2352-4642(21)00095-X) •

Key Points of Ped Endo Reaction

- FH is undiagnosed/ underdiagnosed in children
 - Homozygous is symptomatic and CHD can occur in childhood
 - Heterozygous may be asymptomatic but LDL level is already high
- Early screening and diagnosis is critical to reducing the burden of disease in adulthood
 - Universal screening
 - Selective screening
- Registry - research registry
- Improve the understanding of FH: multisectoral and multidisciplinary
 - Health seeking behavior of parents/ patients
 - Primary health care workers
 - School administrators and health teams
 - Government agencies